Capmatinib (INC280) in MET Delta EX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study

R. S. Heist, J. Wolf, T. Seto, J. -Y. Han, N. Reguart, H. J. M. Groen, D. S. W. Tan, T. Hida, M. D. Jonge, S. V. Orlov, E. F. Smit, P. -J. Souquet, J. Vansteenkiste, M. Giovannini, S. L. Mouhaer, A. Robeva, M. Waldron-Lynch, E. B. Garon

    Research output: Contribution to journalMeeting AbstractAcademic

    Original languageEnglish
    Pages (from-to)S1126
    Number of pages1
    JournalJournal of Thoracic Oncology
    Volume14
    Issue number11
    Publication statusPublished - Nov-2019

    Keywords

    • NSCLC
    • MET
    • INC280
    • Capmatinib

    Cite this